Myeloproliferative Neoplasms

Oncology·MeSH: Myeloproliferative Disorders

Prevalence

5.0 / 100K

8 drugs in development·4 companies·8 clinical trials

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
eltanexor	Karyopharm Therapeutics Inc. (KPTI)
inca033989	Incyte Corp. (INCY)
inca035784	Incyte Corp. (INCY)
inca036978	Incyte Corp. (INCY)

Phase 2(1)

Drug	Company
incb160058	Incyte Corp. (INCY)

Phase 1(1)

Drug	Company
standard disease-directed therapy	Incyte Corp. (INCY)

Preclinical(2)

Drug	Company
cpi-482	CONSTELLATION PHARMACEUTICALS INC (CNST)
JAK2 program	Cogent Biosciences, Inc. (COGT)

BioSniper tracks 8 drugs in development for Myeloproliferative Neoplasms across 4 companies.

There are 8 clinical trials targeting Myeloproliferative Neoplasms tracked by BioSniper.

The estimated prevalence of Myeloproliferative Neoplasms is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.